KMTS
NASDAQKestra Medical Technologies Ltd.
Price$27.27-1.66 (-5.74%)
01:30 PM05:15 PM
News · 26 weeks70-60%
2026-04-192026-10-11
Mix4990d
- SEC Filings21(43%)
- Insider19(39%)
- Other4(8%)
- Analyst2(4%)
- Earnings2(4%)
- Leadership1(2%)
Latest news
25 items- INSIDERDirector Cohen Raymond W sold $97,504 worth of shares (3,330 units at $29.28), decreasing direct ownership by 6% to 54,790 units (SEC Form 4) (tax liability)4 - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Issuer)
- PRKestra Medical Technologies Earns Five-Star Rating on Newsweek’s List of America’s Greatest Mid-Market CompaniesKIRKLAND, Wash., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (NASDAQ:KMTS), a leading wearable medical device and digital healthcare company, has earned a five-star rating on Newsweek’s list of America’s Greatest Mid-Market Companies 2026. Only 30 of the 100 honorees earned five stars, and Kestra was the only company in the Medical Equipment Manufacturing category to receive that rating. "In less than a decade, our team brought the ASSURE® WCD to market and built a rapidly growing commercial business, giving clinicians a differentiated choice for protecting patients during periods of cardiac risk and recovery," said Brian Webster, President and Chief Executive Offi
- SECSEC Form 144 filed by Kestra Medical Technologies Ltd.144 - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Subject)
- PRCAIRDAC Announces the Appointment of Raymond W. Cohen as Chairman of its Board of DirectorsCAIRDAC, SA, a pre-revenue stage medtech company developing a leadless, self-powered cardiac pacemaker (Autonomous Leadless Pacing System), today announced the appointment of Raymond W. Cohen as chairman of its board of directors. "We are thrilled to welcome Mr. Cohen to the CAIRDAC board of directors," said Edouard Fonck, Chief Executive Officer of CAIRDAC, "Ray’s extensive track record in leading, scaling and exiting medical technology companies will, no doubt, be invaluable as we advance this exciting project." Mr. Cohen, an accredited public company director and accomplished medical technology executive, has over four decades of medtech industry experience. He was the co-founder and
- INSIDERDirector Kwo Elizabeth sold $97,268 worth of shares (4,010 units at $24.26), decreasing direct ownership by 22% to 14,116 units (SEC Form 4) (withholding obligation)4 - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Issuer)
- SECSEC Form 144 filed by Kestra Medical Technologies Ltd.144 - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Subject)
- SECSEC Form 10-Q filed by Kestra Medical Technologies Ltd.10-Q - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Filer)
- SECKestra Medical Technologies Ltd. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Filer)
- PRKestra Medical Technologies Reports First Quarter Fiscal 2027 Financial ResultsKIRKLAND, Wash., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (NASDAQ:KMTS), a leading wearable medical device and digital healthcare company, today reported financial results for the first quarter of fiscal year 2027, which ended July 31, 2026. Financial Highlights Generated revenue of $31.0 million in F1Q27, an increase of 60% compared to the prior year period.Expanded gross margin to 56.5% in F1Q27 compared to 45.7% in the prior year period.Increased FY27 revenue guidance to $141 million, representing growth of 48% compared to FY26. "Kestra delivered another strong quarter of financial performance, generating revenue growth of 60% while expanding gross margin
- INSIDERDirector Schwartz Jeffrey Lawrence sold $97,942 worth of shares (3,890 units at $25.18) and was granted 7,217 shares, increasing direct ownership by 30% to 14,236 units (SEC Form 4) to satisfy tax liability4 - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Issuer)
- INSIDERDirector Kwo Elizabeth was granted 7,217 shares, increasing direct ownership by 66% to 18,126 units (SEC Form 4)4 - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Issuer)
- INSIDERDirector Cohen Raymond W was granted 7,217 shares, increasing direct ownership by 14% to 58,120 units (SEC Form 4)4 - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Issuer)
- INSIDERDirector Hanley Conor sold $143,779 worth of shares (5,694 units at $25.25) and was granted 7,217 shares, increasing direct ownership by 13% to 13,489 units (SEC Form 4) (tax liability)4 - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Issuer)
- INSIDERDirector Reilly Kevin C sold $73,677 worth of shares (2,932 units at $25.13) and was granted 7,217 shares, increasing direct ownership by 52% to 12,585 units (SEC Form 4) to cover withholding tax4 - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Issuer)
- INSIDERDirector Ladone Mary Kay sold $98,464 worth of shares (3,908 units at $25.20) and was granted 7,217 shares, increasing direct ownership by 8% to 44,724 units (SEC Form 4) (withholding tax)4 - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Issuer)
- SECKestra Medical Technologies Ltd. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Filer)
- PRKestra Names Daniel Finney Vice President of Research & DevelopmentKIRKLAND, Wash., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (NASDAQ:KMTS), a leading wearable medical device and digital healthcare company, announced today that Daniel Finney has been named Vice President of Research & Development and appointed to the company’s executive leadership team. "Research and development is central to advancing our mission and expanding the role of wearable protection for at-risk patients during critical periods of recovery," said Brian Webster, President and Chief Executive Officer. "The Cardiac Recovery System® platform was designed from the outset to evolve. Dan’s hands-on role in developing the ASSURE® WCD, together with his technic
- SECSEC Form 144 filed by Kestra Medical Technologies Ltd.144 - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Subject)
- SECSEC Form 144 filed by Kestra Medical Technologies Ltd.144 - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Subject)
- PRKestra Medical Technologies to Report First Quarter Fiscal 2027 Financial Results on September 14KIRKLAND, Wash., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (NASDAQ:KMTS), a leading wearable medical device and digital healthcare company, is scheduled to report first quarter fiscal 2027 financial results after the market closes on Monday, September 14. Management will host a conference call at 4:30 p.m. Eastern Time to discuss financial results. A live and archived webcast of the conference call will be available in the "Events" section of the investor relations website. About KestraKestra Medical Technologies, Ltd. is a leading wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using moni
- PRKestra Appoints Curtis Kopf as Senior Vice President of Customer ExperienceKIRKLAND, Wash., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (NASDAQ:KMTS), a leading wearable medical device and digital healthcare company, today announced the appointment of Curtis Kopf as Senior Vice President of Customer Experience. In this newly created role, Mr. Kopf will lead the patient experience from approval of a patient order through completion of therapy and device return, aligning the people, processes and technology that support providers and their patients throughout the use of the ASSURE® WCD. "Our mission is to provide innovative, intuitive medical technologies to protect and support at-risk patients. That mission guides both the technology we cr
- INSIDEROfficer Webster Brian Daniel sold $412,180 worth of shares (15,000 units at $27.48) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 460,215 units (SEC Form 4)4 - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Kestra Medical Technologies Ltd.SCHEDULE 13G/A - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Subject)
- INSIDERChief Financial Officer Mahboob Vaseem sold $680,383 worth of shares (26,287 units at $25.88) as part of a pre-agreed trading plan, decreasing direct ownership by 30% to 60,609 units (SEC Form 4)4 - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Issuer)
- ANALYSTAnalyst initiated coverage on Kestra Medical Technologies with a new price targetAnalyst initiated coverage of Kestra Medical Technologies with a rating of Overweight and set a new price target of $30.00
KMTS FAQ
6 questionsWhere does KMTS stock trade?
Kestra Medical Technologies Ltd. (KMTS) is listed on NASDAQ.What sector and industry is KMTS in?
Kestra Medical Technologies Ltd. operates in the Health Care sector, Medical/Dental Instruments industry.When did Kestra Medical Technologies Ltd. go public?
Kestra Medical Technologies Ltd. (KMTS) completed its IPO in 2025.What are analysts saying about KMTS?
Kestra Medical Technologies Ltd. has had 8 recent analyst actions on file. The most recent action was from Analyst: Overweight with a $3000.00 price target on 2026-08-10. Recent price targets range from $2400.00 to $3200.00.What companies are similar to KMTS?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), BDX (Becton Dickinson and Company), MDLN (Medline Inc.). Compare KMTS side-by-side with any of them on Quantisnow.How can I track KMTS on Quantisnow?
Quantisnow aggregates Kestra Medical Technologies Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow KMTS to receive live email and push alerts on every new disclosure.